Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab in severe pulmonary COVID-19
ISRCTN18205700Phase 2Completed
- Sponsor
- GSK
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and pneumonia comparing Otilimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Proportion alive and free of respiratory failure at Day 28. Started May 2020; status: completed.
02
Drugs
otilimab
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on ISRCTN18205700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18205700.